<DOC>
	<DOCNO>NCT01128998</DOCNO>
	<brief_summary>Primary Objective : 1 . To define recommend dose phase II study S-1 combine sorafenib 2 . To evaluate dose-limiting toxicity combination therapy Secondary Objectives : 1 . To characterize pharmacokinetics ( PK ) sorafenib S-1 combination therapy 2 . To investigate impact genetic polymorphism metabolic gene PK sorafenib S-1 , respectively , well toxicity profile combination . 3 . To determine change biomarkers pre- post-treatments .</brief_summary>
	<brief_title>Sorafenib Plus S-1 Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologically cytologically proven metastatic locally advanced malignant solid tumor , refractory current standard systemic treatment . Have measurable lesion . 2075 y/o . ECOG performance score 2 . Life expectancy &gt; 12 week . Adequate hematopoietic , hepatic renal function . 1 . Hemoglobin &gt; 9.0 g/dl 2 . Absolute neutrophil count &gt; 1,500/mm3 3 . Platelet count 100,000/ mm3 4 . Total bilirubin &lt; 1.5 time upper limit normal ( ULN ) 5 . ALT AST &lt; 2.5 x ULN 6 . Serum creatinine &lt; 1.0 x ULN Recovery prior therapy give &gt; 4 week enrolment . No pregnancy breastfeed . Signed informed consent . Severe cardiovascular disorder . Pulmonary fibrosis interstitial pneumonia . HIV infection . Active infection . Major anticancer treatment within 4 week study entry . Exposure current investigational agent . Known suspect allergy current investigational agent . Unable swallow oral medication . Substance abuse , medical , psychological social condition interfere patient 's participation evaluation study result . Any condition unstable could jeopardize safety patient compliance study . Symptoms bowel obstruction , malnutrition , splenomegaly . Receiving active anticoagulant therapy . Patients concurrent CYP 2A6 and/or CYP 3A4 3A5 inducer inhibitor ; minimal 2 week washout period require .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Sorafenib</keyword>
	<keyword>S1</keyword>
	<keyword>Advanced Solid Tumors</keyword>
	<keyword>RD</keyword>
	<keyword>MTD</keyword>
	<keyword>DLT</keyword>
	<keyword>PK</keyword>
	<keyword>PG</keyword>
	<keyword>Biomarker</keyword>
</DOC>